SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Stocks Crossing The 13 Week Moving Average <$10.01

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jibacoa who wrote (5454)11/17/1999 12:48:00 PM
From: Jibacoa  Read Replies (1) of 13094
 
JIM:

IMAT: Here is today's news:http://dailynews.yahoo.com/h/nm/19991117/tc/imatron_scanner_1.html

They got an OK from the FDA to market the fast scan CT!!!

Now if they get the OK from Medicare to pay for the procedure, after all it is going to save money. According with the article from the Mayo Clinic a few months ago, it could save billions of dollars on hospitalizations just on the patients that go to the ER complaining of chest pains and the ECG is non-diagnostic and are kept overnight pending repeat ECG and cardiac enzymes.

The fast scan CT is supposed to cost around $300 and the diagnostic results are the same as a Thallium stress test that cost 3 or 4 times as much.

I have played this stock in the past on a "seasonal" basis, (like buying the orange juice in the Winter with the freeze scares in FLA or the cocoa in the Summer) buying IMAT a week or so ahead of the Cardiology meetings, has in the past
also given good results ( The last meeting in Atlanta was just a week ago), but now the picture has changed with the FDA approval.

The stock had a nice run a couple of years ago,(I remember it well) up to the 8 level.

Well in spite of the large float, I think is one to keep an eye on.

Regards and good luck.

Bernard

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext